Wealth Alliance Has $228,000 Holdings in Exact Sciences Co. (NASDAQ:EXAS)

Wealth Alliance reduced its holdings in Exact Sciences Co. (NASDAQ:EXAS) by 10.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,082 shares of the medical research company’s stock after selling 350 shares during the quarter. Wealth Alliance’s holdings in Exact Sciences were worth $228,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Segall Bryant & Hamill LLC boosted its holdings in shares of Exact Sciences by 4.7% in the 2nd quarter. Segall Bryant & Hamill LLC now owns 3,315 shares of the medical research company’s stock worth $311,000 after acquiring an additional 150 shares in the last quarter. Harbour Investments Inc. lifted its holdings in Exact Sciences by 0.6% during the 1st quarter. Harbour Investments Inc. now owns 26,279 shares of the medical research company’s stock worth $1,782,000 after buying an additional 162 shares in the last quarter. Strategic Blueprint LLC lifted its holdings in Exact Sciences by 3.1% during the 3rd quarter. Strategic Blueprint LLC now owns 5,449 shares of the medical research company’s stock worth $372,000 after buying an additional 163 shares in the last quarter. Valley National Advisers Inc. lifted its holdings in Exact Sciences by 29.5% during the 3rd quarter. Valley National Advisers Inc. now owns 773 shares of the medical research company’s stock worth $53,000 after buying an additional 176 shares in the last quarter. Finally, Ossiam lifted its holdings in Exact Sciences by 7.5% during the 1st quarter. Ossiam now owns 2,596 shares of the medical research company’s stock worth $176,000 after buying an additional 181 shares in the last quarter. 88.82% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Jacob A. Orville sold 1,879 shares of the company’s stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $56.89, for a total value of $106,896.31. Following the completion of the transaction, the insider now directly owns 11,754 shares of the company’s stock, valued at approximately $668,685.06. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, insider Jacob A. Orville sold 1,879 shares of the company’s stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $56.89, for a total value of $106,896.31. Following the completion of the transaction, the insider now directly owns 11,754 shares of the company’s stock, valued at approximately $668,685.06. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Jacob A. Orville sold 966 shares of the stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $61.43, for a total transaction of $59,341.38. Following the transaction, the insider now owns 7,488 shares of the company’s stock, valued at $459,987.84. The disclosure for this sale can be found here. In the last ninety days, insiders sold 69,113 shares of company stock valued at $4,165,273. Company insiders own 1.30% of the company’s stock.

Exact Sciences Price Performance

Shares of NASDAQ EXAS opened at $60.96 on Friday. The firm has a market cap of $11.07 billion, a PE ratio of -53.47 and a beta of 1.25. The company has a current ratio of 2.32, a quick ratio of 2.07 and a debt-to-equity ratio of 0.74. Exact Sciences Co. has a 1-year low of $56.05 and a 1-year high of $100.77. The company has a fifty day moving average price of $63.42 and a 200 day moving average price of $65.06.

Exact Sciences (NASDAQ:EXAS) last announced its earnings results on Wednesday, February 21st. The medical research company reported ($0.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.26. The firm had revenue of $646.89 million during the quarter, compared to analyst estimates of $638.83 million. Exact Sciences had a negative net margin of 8.17% and a negative return on equity of 6.60%. The company’s revenue for the quarter was up 17.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.72) EPS. Research analysts predict that Exact Sciences Co. will post -0.86 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have issued reports on EXAS shares. Benchmark raised Exact Sciences from a “hold” rating to a “buy” rating and set a $91.00 price objective on the stock in a report on Tuesday, January 2nd. TheStreet downgraded Exact Sciences from a “c-” rating to a “d+” rating in a report on Monday, February 26th. Citigroup reaffirmed a “buy” rating and set a $100.00 price objective on shares of Exact Sciences in a report on Wednesday, April 3rd. William Blair reiterated an “outperform” rating on shares of Exact Sciences in a research report on Thursday, February 22nd. Finally, Canaccord Genuity Group dropped their target price on shares of Exact Sciences from $100.00 to $90.00 and set a “buy” rating for the company in a research report on Thursday, February 22nd. Three analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $97.44.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.